SRPK-IN-1 effectively converts VEGF from pro-angiogenic to anti-angiogenic isoform. SRPKIN-1 treatment at 200 nM (10, 50, 100, 200 nM, 16 hours) obviously decreases SR protein phosphorylation at the steady-state with or without washout [1].

SRPKIN-1 (50 nM, 300 nM,1 μL, 5 times) blocks angiogenesis through VEGF alternative splicing in a CNV mouse model [1].